During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl
groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to …

Most prostate cancers are androgen-sensitive malignancies whose growths depend on the
transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins …

Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the
treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy …

Histone acetyltransferases (HATs) are implicated as both oncogene and nononcogene
dependencies in diverse human cancers. Acetyl-CoA-competitive HAT inhibitors have …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …